Skip to content

Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass

Prospective Randomized Study of Glutamin Protective Properties in Cardiac Surgery.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01478126
Enrollment
24
Registered
2011-11-23
Start date
2012-01-31
Completion date
2013-09-30
Last updated
2013-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

The purpose of this study is to determine whether perioperative glutamine administration possess protective properties on internal organs (heart and gut) in patients with coronary atherosclerosis, operated under cardiopulmonary bypass.

Interventions

Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.

DRUGPlacebo

Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.

Sponsors

Meshalkin Research Institute of Pathology of Circulation
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients with coronary artery disease operated on under cardiopulmonary bypass

Exclusion criteria

* Ejection fraction\<40% * Viral hepatitis * Liver cirrhosis * Cholecystitis * Pancreatitis * Chronic severe gastrointestinal disease * Surgery on gastrointestinal tract in patient's medical history

Design outcomes

Primary

MeasureTime frame
Troponin IInduction to anaesthesia, 30 min after cardiopulmonary bypass, 6, 24 hours after CPB

Secondary

MeasureTime frameDescription
Intestinal fatty acid binding proteinInduction to anaesthesia (0 hour of operation), before heparin injection (1 hour of operation), 5min after aorta unclaming, 2, 6, 24 hours after CPBIntestinal fatty acid binding protein
alpha-glutathione s-transferaseInduction to anaesthesia (0 hour of operation), before heparin injection (1 hour of operation), 5min after aorta unclaming, 2, 6, 24 hours after CPBalpha-glutathione s-transferase
Alanine Aminotransferase (ALT)Induction to anaesthesia (0 hour of operation), before heparin injection (1 hour of operation), 5min after aorta unclaming, 2, 6, 24 hours after CPB
Liver Fatty Acid Binding ProteinInduction to anaesthesia (0 hour of operation), before heparin injection (1 hour of operation), 5min after aorta unclaming, 2, 6, 24 hours after CPBLiver fatty acid binding protein
Serum HSP-70Induction to anaesthesia (0 hour of operation), before heparin injection (1 hour of operation), 5min after aorta unclaming, 2, 6, 24 hours after CPB
GlutathioneInduction to anaesthesia (0 hour of operation), before heparin injection (1 hour of operation), 5min after aorta unclaming, 2, 6, 24 hours after CPB
SH-groupsInduction to anaesthesia (0 hour of operation), before heparin injection (1 hour of operation), 5min after aorta unclaming, 2, 6, 24 hours after CPB
Aspartate transaminase (AST)Induction to anaesthesia (0 hour of operation), before heparin injection (1 hour of operation), 5min after aorta unclaming, 2, 6, 24 hours after CPB

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026